Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&T Committees May Be Redefined By Medicare Regs

Executive Summary

The Medicare implementing regulations will have a profound impact on the operations of pharmacy and therapeutics committees, Medco Government Affairs Consultant Terry Latanich told the P&T Society's recent annual conference
Advertisement

Related Content

Medicare Part D Could Alleviate “Bias” In Formulary Decisions
Medicare Part D Could Alleviate “Bias” In Formulary Decisions
Medicare P&T Committees Can Consider Costs, But Only In Broad Context
Medicare P&T Committees Can Consider Costs, But Only In Broad Context
P&T Committees Would Be Powerful Force Under Medicare Rx
P&T Committees Would Be Powerful Force Under Medicare Rx
Medicare Part D Regs Coming Soon; CMS Plans To Finalize Regions In 2004
Medicare Part D Regs Coming Soon; CMS Plans To Finalize Regions In 2004
Medco Pays $29.3 Mil. To 20 States; Buys Chance To Write PBM Rules
Advertisement
UsernamePublicRestriction

Register

PS043991

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel